Healthy
Conditions
Keywords
Healthy, JNJ-42721458, Male, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity
Brief summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (what the body does to the medication), potential immunogenicity (ability to induce an immune response), and pharmacodynamics (what the drug does to the body) after administration of JNJ-42721458 in healthy adult male participants.
Detailed description
This is a randomized (the study medication is assigned by chance), double-blind (neither physician nor participant knows the identity of the assigned treatment), placebo-controlled (an inactive substance that is compared with a medication to test whether the medication has a real effect in a clinical study), single-ascending (increasing) dose and multiple-ascending dose study of JNJ-42721458 compound in healthy males. The study is divided in two parts. Part 1 is a single-ascending dose (SAD) study which will include up to 10 panels (using ascending doses starting from 0.1 mg) in which a single dose of the study medication will be administered on Day 1. Part 2 is a multiple-ascending dose (MAD) study which will include approximately 6 panels (using ascending doses starting from 5.0 mg) in which multiple doses of study medication will be administered once daily for 10 days. Part 2 will be initiated after completion of dosing and all relevant evaluations from Part 1. In each panel of Part 1 and 2, 6 participants will be randomly assigned to receive JNJ-42721458 and 2 participants randomly assigned to placebo. Safety evaluations will include assessment of adverse events, physical examinations, laboratory tests, vital signs, electrocardiograms, cardiac telemetry and evaluation of injection sites which will be monitored throughout the study. The total study duration for each participant will be approximately 6-7 weeks in Part 1 and 7-8 weeks for each participant in Part 2.
Interventions
DRUGJNJ-42721458 (single dose)
JNJ-42721458 will be administered subcutaneously (an injection under the skin) as single doses, starting from 0.1 mg.
DRUGJNJ-42721458 (multiple doses)
JNJ-42721458 will be administered subcutaneously (an injection under the skin) once daily, starting with a dose of 5.0 mg.
Matching placebo will be administered subcutaneously (an injection under the skin) as a single dose in Part 1.
DRUGPlacebo (multiple doses)
Matching placebo will be administered subcutaneously (an injection under the skin) once daily for 10 days in Part 2.
Sponsors
Janssen Research & Development, LLC
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
MALE
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
* Body mass index (weight kg/m2) between 18 and 30 kg/m2, and body weight not less than 50 kg * Participant is judged to be generally in good health based on medical history, physical examination, vital signs and laboratory safety tests * Blood pressure between 90 and 135 mmHg systolic, inclusive, and no higher than 90 mmHg diastolic * A 12-lead electrocardiogram consistent with normal cardiac conduction and function
Exclusion criteria
* History of or current clinically significant medical illness * Clinically significant abnormal values for hematology, clinical chemistry or urinalysis at screening or on Day -1 (at admission to the study center) * Estimated creatinine clearance of less than or equal to 80 mL/min * Clinically significant abnormal physical examination, vital signs or 12 lead electrocardiogram at screening or on Day -1 * Participant demonstrates orthostatic change in vital signs measurements on screening or predose while going from a semi recumbent to standing position * History of significant multiple and/or severe allergies (including latex allergies) or known history of clinically significant allergies to polyethylene glycol (PEG) containing or other PEGylated products
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Part 1 and 2: Apparent volume of distribution after subcutaneous administration of JNJ-42721458 | Up to Day 10 (for Part 1) and Day 27 (for Part 2) | — |
| Part 1 and 2: Terminal half-life (t1/2) of JNJ-42721458 | Up to Day 10 (for Part 1) and Day 27 (for Part 2) | — |
| Part 1 and 2: Apparent systemic clearance of drug after subcutaneous administration of JNJ-42721458 | Up to Day 10 (for Part 1) and Day 27 (for Part 2) | — |
| Part 1 and 2: Plasma levels of antibodies to JNJ-42721458 for evaluation of potential immunogenicity | Up to Day 10 (for Part 1) and Day 27 (for Part 2) | — |
| Part 1 and 2: Number of participants with adverse events | Up to 17 weeks | Number of participants with adverse events will be used as a measure of safety and tolerability. |
| Part 1 and 2: Maximum observed concentration (Cmax) of JNJ-42721458 | Up to Day 10 (for Part 1) and Day 27 (for Part 2) | — |
| Part 1 and 2: Time to reach the maximum plasma concentration (tmax) of JNJ-42721458 | Up to Day 10 (for Part 1) and Day 27 (for Part 2) | — |
| Part 1 and 2: Area under the concentration-time curve of JNJ-42721458, from time 0 to infinity, with extrapolation of the terminal phase | Up to Day 10 (for Part 1) and Day 27 (for Part 2) | — |
| Part 1 and 2: Area under the concentration-time curve of JNJ-42721458 during a dosing interval at steady state | Up to Day 10 (for Part 1) and Day 27 (for Part 2) | — |
Secondary
| Measure | Time frame |
|---|---|
| Part 1 and 2: Change from baseline in resting peripheral blood pressure | Up to Day 10 (for Part 1) and Day 27 (for Part 2) |
| Part 1 and 2: Change from baseline in resting heart rate | Up to Day 10 (for Part 1) and Day 27 (for Part 2) |
Countries
Belgium
Outcome results
None listed